1.14
0.06 (5.56%)
| 前收盘价格 | 1.08 |
| 收盘价格 | 1.08 |
| 成交量 | 21,499 |
| 平均成交量 (3个月) | 101,008 |
| 市值 | 14,010,867 |
| 预期市盈率 (P/E Forward) | 1.00 |
| 价格/销量 (P/S) | 0.370 |
| 52周波幅 | |
| 利润日期 | 25 Mar 2026 |
| 营业毛利率 | -86.05% |
| 营业利益率 (TTM) | -130.50% |
| 稀释每股收益 (EPS TTM) | -14.22 |
| 季度收入增长率 (YOY) | -40.50% |
| 季度盈利增长率 (YOY) | 32.10% |
| 流动比率 (MRQ) | 2.09 |
| 营业现金流 (OCF TTM) | -43.13 M |
| 杠杆自由现金流 (LFCF TTM) | -20.05 M |
| 资产报酬率 (ROA TTM) | -52.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Allurion Technologies, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.63 |
|
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 11.67% |
| 机构持股比例 | 46.24% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Rtw Investments, Lp | 31 Dec 2025 | 5,891,430 |
| Lunt Capital Management, Inc. | 31 Dec 2025 | 166,666 |
| Anson Funds Management Lp | 31 Dec 2025 | 59,881 |
| Empery Asset Management, Lp | 31 Dec 2025 | 59,881 |
| Hudson Bay Capital Management Lp | 31 Dec 2025 | 59,880 |
| L1 Global Manager Pty Ltd | 31 Dec 2025 | 59,880 |
| Heights Capital Management, Inc | 31 Dec 2025 | 59,880 |
| Unisphere Establishment | 31 Dec 2025 | 49,695 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合